This morning Geyser Brands (CSE: GYSR) announced they have been awarded a research license from Health Canada.
With the awarded Research License, Geyser Brands will develop new formulations for topicals, edibles, and beverages related to cannabis. The Company has already completed all of its research and planning for the next phase, and with the granting of their Research License, will now commence converting the work into real-life wellness products that have top-tier formulations.
Geyser Brands’ fully operational R&D laboratory in Vancouver, BC will now develop cannabis-based products as well as operate as a pilot-scale production for the transformation of cannabis-CBD based ingredients and organic formulation
We now have the opportunity to act on expanding our product development and innovation efforts through new proprietary formulations with the intent to bring cannabis to the mainstream. We look forward to working with some of our existing partners to utilize our next phase of growth and development at Geyser Brands.
Andreas Thatcher, CEO, Geyser Brands
The Research License is the third license granted to Geyser Brands, after already receiving their Cultivation and Processing Licenses in October 2018 and June 2019, respectively. In addition, the Company is in the process of obtaining their final license for Medical and Retail Sales.
Geyser Brands last traded at $0.25 on the TSX Venture.
FULL DISCLOSURE: Geyser Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Geyser Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
